Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Chief Medical Officer | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 680,403 |
Ending reported balance
After 2024-06-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-20 · Purchase · Acquired 190,000 · Balance 565,403 F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Row 2 · 2024-06-21 · Purchase · Acquired 115,000 · Balance 680,403 F2: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2024 Filed Jun 24, 2024 20:29 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 115,000 | $0.27 | $30,716.50 |
DisclosureSEC source: 0001415889-24-017978 · form4-06242024_080643.xml · nonDerivative · entry 2 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,403 F2 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:29 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 190,000 | $0.25 | $48,108.00 |
DisclosureSEC source: 0001415889-24-017978 · form4-06242024_080643.xml · nonDerivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,403 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:05 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-24-001740 · doc4.xml · derivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-11 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 20:21 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 30,403 | $1.38 | $41,956.14 |
DisclosureSEC source: 0001209191-23-050476 · doc4.xml · nonDerivative · entry 2 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,403 F2 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.37 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 20:21 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 35,000 | $1.38 | $48,300.00 |
DisclosureSEC source: 0001209191-23-050476 · doc4.xml · nonDerivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.35 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:02 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 244,800 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-23-004212 · doc4.xml · derivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,800 Underlying: Common Stock · 244,800 shares Expires 2033-01-18 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:41 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 110,000 | $2.25 | $247,500.00 |
DisclosureSEC source: 0001209191-22-062741 · doc4.xml · nonDerivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $2.20 to $2.25 per share, with a weighted average purchase price of $2.25 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:26 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 100,000 | $1.66 | $166,000.00 |
DisclosureSEC source: 0001209191-22-057314 · doc4.xml · nonDerivative · entry 2 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F2 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.52 to $1.75 per share, with a weighted average purchase price of $1.66 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:26 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 100,000 | $1.43 | $143,000.00 |
DisclosureSEC source: 0001209191-22-057314 · doc4.xml · nonDerivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.31 to $1.55 per share, with a weighted average purchase price of $1.43 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:10 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee stock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-22-048996 · doc4.xml · derivative · entry 1 Rock Edwin · CIK 0001945417 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-09-01 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on September 2, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.